World NTD Day 2020
#BeatNTDs: For good. For all
Thursday 30 January marks the first World NTD Day
Neglected Tropical Diseases threaten more than 1,5 billion people living in the poorest and most marginalised communities worldwide. LSTM is one of the more than 250 organisations which have signed up to mark this day to raise awareness and mobilise greater attention, action, and investment to ensure progress continues to be made in combatting these debilitating diseases.
LSTM is at the forefront of Neglected Tropical Diseases (NTDs) research and works to identify critical bottlenecks in the field of NTDs through its research and implementation activities, whilst evaluating alternative strategies to overcome the existing barriers and to improve strategies for their control and elimination.
LSTM focuses on a multidisciplinary approach to NTDs building on the particular strengths of its academic departments. This draws together a broad range of existing NTD expertise and creates new areas for collaborative programmes across LSTM.
LSTM’s Centre for Neglected Tropical Diseases (CNTD) continued their key role in the implementation of control and elimination NTD programmes with a new £15m three-year award from DFID’s Accelerating the Control and Elimination of Neglected Tropical Disease (ASCEND) programme targeting five of the worst NTDs: lymphatic filariasis, onchocerciasis, schistosomiasis, visceral leishmaniasis and trachoma in 25 of the world’s poorest countries.
World NTD Day Seminar
On the eve of the first ever World NTD Day, the seminar showcased LSTM’s newly expanded Centre for Neglected Tropical Diseases with speed talks to illustrate the breadth of translational research and impacts of our neglected tropical disease activities.
The discovery and development of A·WOL’s first candidate selected anti-wolbachial drug, a re-purposed macrolide ABBV-4083 (TylaMac), was published in Science Translational Medicine and has successfully completed Phase I testing in humans and is now progressing to Phase II testing in DRC in partnership with Abbvie and DNDi.
The highly selective anti-wolbachial drug, AWZ1066 was published in the Proceedings of the National Academy of Science and is undergoing formal pre-clinical development through MRC DPFS funding in partnership with Eisai.
Other publications include our collaboration with AstraZeneca’s High-Throughput Screening Group to screen 1.3m compounds from AZ’s collection in just 10 weeks generating 20,000 hits and 9 chemical series with rapid and potent anti-wolbachial activity as published in Nature Communications.
A·WOL is also working to identify the targets of our new drugs and to understand the mode-of-action of our new rapid-kill compounds with the aim to further reduce the treatment regimens for onchocerciasis and lymphatic filariasis.
A new focus on genital schistosomiasis in women and men
As part of expanded workplans of COUNTDOWN, it has recently drawn attention to female genital schistosomiasis (FGS) in Ghana and for health systems to adapt and respond appropriately.
Using a qualitative method approach, community members and associated health workers were interviewed to find widespread misconceptions about FGS. The signs and symptoms of this disease were confused with other sexually transmitted infections such that adolescent girls who reported with vaginal discharge and itching were often stigmatised by health workers for promiscuity, which left their FGS incorrectly managed.
Looking to the future, integration of praziquantel treatment within sexual and reproductive health services in primary health care services may raise the profile of this unrecognised condition and provide guidelines for its treatment.
Urogenital schistosomiasis is caused by infection with Schistosoma haematobium, an important parasitic disease in sub-Saharan Africa and is well-known to cause significant damage to the urinary tract.
This aspect of disease gives rise to either female genital schistosomiasis (FGS) or male genital schistosomiasis (MGS), where eggs of the parasite damage the internal or external genitalia. To draw international attention on this aspect of disease, several LSTM staff assisted COR-NTD to hold a discussion workshop in Liverpool, to assess its importance with HIV infection, cervical cancers and women’s wellbeing in general.
With regard to MGS, a systematic review of cases reported across the globe has been conducted by PhD student Dr Seke Kayuni, a research clinician from Malawi. Many adult fishermen who are on antiretroviral therapy exhibit classic MGS where eggs of S. haematobium can be found in semen, as well as cause overt damage to tissues. Since all current diagnostics in use for MGS are imperfect, it is important to take an integrated diagnostic approach to better manage MGS patients.